Jesse M. Cedarbaum

A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials

J. Cedarbaum, N. Stambler, C. Fuller, 1999, Journal of the Neurological Sciences.

Revision of the criteria for Alzheimer's disease: A symposium

Ronald C. Petersen, Richard Frank, Michael Gold, 2011, Alzheimer's & Dementia.

Performance of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) in multicenter clinical trials

J. Cedarbaum, N. Stambler, Nancy Stambler, 1997, Journal of the Neurological Sciences.

Biometric monitoring devices for assessing end points in clinical trials: developing an ecosystem

Sean Khozin, George Vradenburg, Daniel R. Karlin, 2017, Nature Reviews Drug Discovery.

Digital technologies as biomarkers, clinical outcomes assessment, and recruitment tools in Alzheimer's disease clinical trials

Ioannis Tarnanas, Sara J. Czaja, Michael Gold, 2018, Alzheimer's & dementia.

Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer’s disease clinical trials

Bruno Vellas, Michael Grundman, Sandrine Andrieu, 2013, Alzheimer's & Dementia.

FDG PET Parkinson’s disease-related pattern as a biomarker for clinical trials in early stage disease

Stephen C. Strother, Miles N. Wernick, Nir Giladi, 2018, NeuroImage: Clinical.

Mild cognitive impairment: Disparity of incidence and prevalence estimates

H. Arrighi, J. Cedarbaum, A. Ward, 2012, Alzheimer's & Dementia.